MD Anderson Ovarian SPORE publications – 2004
1.
Albarracin CT, Silva EG, Malpica A, Luthra R, Liu J. The role of hMSH3 and hMSH6 in ovarian
endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep
12(6):1217-9, 2004. PMID: 15547740.
2.
Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ. Expression of platelet-derived growth
factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian
carcinoma cell lines. Gynecol Oncol 93(1):78-86, 2004. PMID: 15047217.
3.
Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in
antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10(3):897-908, 2004. PMID:
14871965.
4.
Baggerly KA, Edmonson SR, Morris JS, Coombes KR. High-resolution serum proteomic patterns
for ovarian cancer detection. Endocr Relat Cancer 11(4):583-4; author reply 5-7, 2004. PMID:
15613439.
5.
Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum:
comparing datasets from different experiments. Bioinformatics 20(5):777-85, 2004. PMID:
14751995.
6.
Bast RC Jr. Early detection of ovarian cancer: new technologies in pursuit of a disease that is
neither common nor rare. Trans Am Clin Climatol Assoc 115:233-47; discussion 47-8, 2004. PMID:
17060970; PMCID: PMC2263776.
7.
Baykal A, Thompson JA, Xu XC, Hahn WC, Deavers MT, Malpica A, Gershenson DM, Silva EG, Liu J.
In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic
ovarian tissues. Oncol Rep 11(2):297-302, 2004. PMID: 14719058.
8.
Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Retrospective
analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol
95(3):564-9, 2004. PMID: 15581964.
9.
Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The activity of
taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22(17):3517-23, 2004.
PMID: 15337800.
10.
Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite
instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma.
Hum Pathol 35(5):552-9, 2004. PMID: 15138928.
11.
Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in
ovarian cancer patients. J Clin Oncol 22(5):881-9, 2004. PMID: 14990644.
12.
Chen CM, Behringer RR. Ovca1 regulates cell proliferation, embryonic development, and
tumorigenesis. Genes Dev 18(3):320-32, 2004. PMID: 14744934; PMCID: PMC338284.
13.
Chen CM, Chang JL, Behringer RR. Tumor formation in p53 mutant ovaries transplanted into wildtype female hosts. Oncogene 23(46):7722-5, 2004. PMID: 15334065.
14.
Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH,
Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian
and breast cancers. Nat Med 10(11):1251-6, 2004. PMID: 15502842.
15.
Cheng KW, Lahad JP, Mills GB. Analysis of molecular aberrations in ovarian cancer allows novel
target identification. J Obstet Gynaecol Can 26(5):461-74, 2004. PMID: 15151733.
16.
Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R. Brain metastases
in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol 66(3):313-25,
2004. PMID: 15015663.
17.
Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW,
Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM.
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy
and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-24, 2004. PMID:
15122311.
18.
Donato ML, Levenback C, Gershenson DM, McMeekin S, Champlin RE. Matched unrelated donor
bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case
report. Gynecol Oncol 92(1):365-7, 2004. PMID: 14751187.
19.
Euscher ED, Silva EG, Deavers MT, Elishaev E, Gershenson DM, Malpica A. Serous carcinoma of
the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol
28(9):1217-23, 2004. PMID: 15316322.
20.
Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB.
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J
Biol Chem 279(10):9653-61, 2004. PMID: 14670967.
21.
Frausto SD, Geisler JP, Fletcher MS, Sood AK. Late recurrence of juvenile granulosa cell tumor of
the ovary. Am J Obstet Gynecol 191(1):366-7, 2004. PMID: 15295395.
22.
Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation - A microenvironment for
Epithelial Ovarian Cancer (EOC). J Transl Med 2(1):23, 2004. PMID: 15219235; PMCID:
PMC459521.
23.
Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer:
case-control analysis of toxicity. Am J Clin Oncol 27(1):14-8, 2004. PMID: 14758127.
24.
Hu W, Wu W, Kobayashi R, Kavanagh JJ. Proteomics in cancer screening and management in
gynecologic cancer. Curr Oncol Rep 6(6):456-62, 2004. PMID: 15485615.
25.
Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB.
Molecular therapeutics: promise and challenges. Semin Oncol 31(1 Suppl 3):39-53, 2004. PMID:
15052542.
26.
Landen CN, Klingelhutz A, Coffin JE, Sorosky JI, Sood AK. Genomic instability is associated with
lack of telomerase activation in ovarian cancer. Cancer Biol Ther 3(12):1250-3, 2004. PMID:
15477760.
27.
Lee CM, Lo HW, Shao RP, Wang SC, Xia W, Gershenson DM, Hung MC. Selective activation of
ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res
64(5):1788-93, 2004. PMID: 14996741.
28.
Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra
R. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian
endometrioid cancer. Mod Pathol 17(1):75-80, 2004. PMID: 14631366.
29.
Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N,
Yu Y, Hahn WC, Mills GB, Bast RC Jr. A genetically defined model for human ovarian cancer.
Cancer Res 64(5):1655-63, 2004. PMID: 14996724.
30.
Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB, Fang X. Glycogen synthase
kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal
kinase. J Biol Chem 279(49):51075-81, 2004. PMID: 15466414.
31.
Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J,
Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM,
Mills GB, Bast RC Jr. Selection of potential markers for epithelial ovarian cancer with gene
expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-300,
2004. PMID: 15161682.
32.
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian
serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496-504, 2004. PMID:
15087669.
33.
Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin Oncol 31(6 Suppl 16):10-7;
discussion 33, 2004. PMID: 15799239.
34.
Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K,
Hortobagyi GN, Kavanagh JJ, Smith JA. An assessment of the utilization of complementary and
alternative medication in women with gynecologic or breast malignancies. J Clin Oncol
22(4):671-7, 2004. PMID: 14966090.
35.
Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan
BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC,
Zempolich K, Dubeau L. Detection of residual subclinical ovarian carcinoma after completion of
adjuvant chemotherapy. Clin Cancer Res 10(8):2681-6, 2004. PMID: 15102671.
36.
Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF, Jr, Goodman A, Seiden MV. Expression of
multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in
ovarian cancer patients: a study in serial samples. Gynecol Oncol 93(1):98-106, 2004. PMID:
15047220.
37.
Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande C, Schneider S, Keitz B, Driscoll D, Ritter
G, Lele S, Sood A, Old LJ, Odunsi K. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLADPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun 4:12, 2004. PMID:
15521719.
38.
Ramalingam P, Malpica A, Silva EG, Gershenson DM, Liu JL, Deavers MT. The use of cytokeratin 7
and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell
carcinomas. Am J Surg Pathol 28(11):1499-505, 2004. PMID: 15489654.
39.
Ramirez PT, Frumovitz M, Wolf JK, Levenback C. Laparoscopic port-site metastases in patients
with gynecological malignancies. Int J Gynecol Cancer 14(6):1070-7, 2004. PMID: 15571612.
40.
Ramondetta LM, Tortolero-Luna G, Bodurka DC, Sills D, Basen-Engquist K, Gano J, Levenback C.
Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J
Gynecol Cancer 14(4):580-8, 2004. PMID: 15304150.
41.
Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray
technology in ovarian carcinoma. Mod Pathol 17(7):790-7, 2004. PMID: 15073602.
42.
Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC Jr. Expression of the tumor
suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of
p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10(19):6559-66, 2004.
PMID: 15475444.
43.
Samanta AK, Huang HJ, Bast RC Jr, Liao WS. Overexpression of MEKK3 confers resistance to
apoptosis through activation of NFkappaB. J Biol Chem 279(9):7576-83, 2004. PMID: 14662759.
44.
See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest 22 Suppl 2:29-44,
2004. PMID: 15573743.
45.
Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of
transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell
motility. Cancer Res 64(10):3550-8, 2004. PMID: 15150111.
46.
Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas
RP, Jacobs IJ, Zhang Z, Bast RC Jr. Preoperative sensitivity and specificity for early-stage
ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage
colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol
22(20):4059-66, 2004. PMID: 15381683.
47.
Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH.
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84
cases. Gynecol Oncol 94(2):456-62, 2004. PMID: 15297188.
48.
Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller
MD, Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in
migration and invasion. Am J Pathol 165(4):1087-95, 2004. PMID: 15466376; PMCID: PMC1618649.
49.
Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ.
Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol
190(4):899-909, 2004. PMID: 15118611.
50.
Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sequential
intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant
ovarian carcinoma: results of a phase II trial. Clin Cancer Res 10(18 Pt 1):6080-5, 2004. PMID:
15447993.
51.
Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K,
Nozawa S. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101),
induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor
agent for clear cell adenocarcinoma. Gynecol Oncol 94(3):643-9, 2004. PMID: 15350353.
52.
Tangjitgamol S, See HT, Manusirivithaya S, Levenback CF, Gershenson DM, Kavanagh JJ. Third-line
chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary
peritoneal carcinoma patients. Int J Gynecol Cancer 14(5):804-14, 2004. PMID: 15361188.
53.
Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for
ovarian cancer: a comprehensive review. Dis Markers 20(2):53-70, 2004. PMID: 15322314; PMCID:
PMC3839278.
54.
Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood
AK. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer
Res 10(15):5145-50, 2004. PMID: 15297418.
55.
Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T,
Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB.
Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem
92(6):1115-40, 2004. PMID: 15258897.
56.
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB.
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line
chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682-91, 2004. PMID: 15547181.
57.
Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson DM, Broaddus R, Liu J, Arap W,
Pasqualini R. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from
ovarian cancer patients. Oncogene 23(55):8859-67, 2004. PMID: 15480432.
58.
Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, Levenback C, Gershenson
DM. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxelresistant epithelial ovarian cancer. Gynecol Oncol 94(2):442-8, 2004. PMID: 15297186.
59.
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J. Inhibition of breast and ovarian tumor
growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA
against Her-2/neu gene expression. J Biol Chem 279(6):4339-45, 2004. PMID: 14625284.
60.
Yoshida H, Cheng W, Hung J, Montell D, Geisbrecht E, Rosen D, Liu J, Naora H. Lessons from
border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human
ovarian cancer. Proc Natl Acad Sci U S A 101(21):8144-9, 2004. PMID: 15146066; PMCID:
PMC419571.
61.
Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. Activation of antioxidant
pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells
revealed by functional proteomics and mass spectrometry. Cancer Res 64(13):4577-84, 2004.
PMID: 15231669.
62.
Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY,
Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET,
Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early
stage ovarian cancer. Cancer Res 64(16):5882-90, 2004. PMID: 15313933.